Direxion Daily LLY Bull 2X Shares

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

Eli Lilly's Q1 2026 revenue soars 56%, topping global pharmaceutical sales charts

Eli Lilly and Company to Participate in EASD Industry Symposium

Institutional Investors Show Mixed Changes in Eli Lilly Holdings

Eli Lilly Announces Additional $4.5 Billion Investment to Expand US Manufacturing Capacity for Weight-Loss Therapies

Multiple institutional investors increased their stakes in Eli Lilly and Company during the recent reporting period.

Eli Lilly is expected to release pivotal Phase 3 clinical trial data for its highly anticipated obesity drug, Retatrutide.

Millennium Capital Advisors takes a new $3.94 million position in Eli Lilly, report says

Eli Lilly gains attention for positive trial data on its next-generation weight-loss drug, Retatrutide.

Eli Lilly fined for advertising weight-loss drugs in France

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

IBBQ

ELIS

ELIL

LLYX

The U.S. Supreme Court denied Eli Lilly's petition, finalizing a $220M judgment for defrauding the Medicaid Drug Rebate Program. This marks a significant victory for whistleblower Ronald J. Streck and his legal team after a 12-year legal battle. The case, initiated in 2014, revealed that Eli Lilly failed to pay required Medicaid rebates following price increases. This decision upholds a unanimous jury verdict and highlights the success of False Claims Act litigation.

prnewswire

Eli Lilly

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Direxion Daily LLY Bear 1X Shares

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Defiance Daily Target 2X Long LLY ETF

ALPS Medical Breakthrough

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

PUBT

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

The company is riding an incredible tailwind.

iShares Global Healthcare

Eli Lilly stock: Next stop $2,000?

Eli Lilly has partnered with Caitlin Clark’s foundation to open three multisport community courts in Indianapolis, including two at public schools and one in a park. This initiative is part of Lilly's 150th anniversary celebrations, with the courts designed for basketball, soccer, and futsal. The project involves Musco Lighting and aims to enhance community access to sports facilities. Lilly's campaign, '150 Years of Everything Else,' promotes its brand through various media.

Fiercepharma

Lilly allies with Caitlin Clark for Indianapolis sports courts

Trump purchased up to $680,000 in Eli Lilly stock amid favorable federal policies for its obesity drugs. Legal ethicists express concerns about the timing potentially undermining public trust, although Trump's team claims the trades are independently managed. This move reflects a broader shift from bonds to numerous stock trades linked to administration policies.

Trump purchased Eli Lilly stock as policies favored its drugs

LLYZ

LABD

Eli Lilly was among the pharmaceutical companies denied certiorari by the Supreme Court, which rejected multiple appeals related to healthcare and commercial cases. This decision diminishes the chances of immediate Supreme Court intervention in these matters. Following the news, Eli Lilly's shares fell by 2.2% to $985.25.

fidelity

Defiance Daily Target 2X Short LLY ETF

Direxion S&P Biotech Bear 3X

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) has emerged as a leader in the obesity drug market with its GLP-1 based products, Mounjaro and Zepbound, significantly boosting its stock. However, concerns about policy uncertainties and elevated expectations suggest that the market may have already priced in much of the growth potential. While demand for obesity treatments remains strong, potential risks could lead to volatility, prompting a neutral stance on LLY.

Tip Ranks

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

StockTitan

AllianceBernstein

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

Representative Byron Donalds (Republican-Florida) purchased shares of Eli Lilly and Company (NYSE: LLY) valued between $1,001 and $15,000 on April 2nd, as disclosed in a filing on May 13th. The stock has seen a recent decline, trading down $1.51 to $1,005.20. Eli Lilly reported strong quarterly earnings, beating estimates with $8.55 EPS and $19.80 billion in revenue, and declared a quarterly dividend of $1.73 per share.

Market Beat

Novo Nordisk AS

Hims & Hers Health

Chipotle Mexican Grill

Intuit

Marvell Tech

Netflix

Trade Desk

Paypal

Viking Therap

Daiwa Securities Group Inc.

Barclays

Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Byron Donalds

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth | LLY Stock News